Episode
2382: 2026 Could Be a Defining Year for POLB 001 and Oral GLP-1
- Podcast
- The Vox Markets Podcast
- Published
- Apr 28, 2026
- Duration seconds
- 777
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8896364
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2382-2026-could-be-a-defining-year-for-polb-001-and-oral-glp-1.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.